Safety and Efficacy of Intravenous Tranexamic Acid in Endoscopic Transurethral Resections in Urology
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
Transurethral resection of the prostate (TURP) represents the gold standard in the operative
management of benign prostatic hyperplasia (BPH) and the transurethral resection of bladder
tumor (TURBT) is the first-line surgical treatment for bladder tumors. One of the most
important complications of urological endoscopic resections is intraoperative and
postoperative bleeding requiring blood transfusion. Allogeneic blood transfusion is not free
of risks, like infection transmission, hemolytic reactions, transfusion-related lung injury,
fluid overload, increased costs and hospital length of stay.
Tranexamic acid (TXA) is a synthetic analog of serin than reversibly inhibits fibrinolysis by
blocking lysine union sites in the plasmin and plasminogen activator molecules. TXA has been
used to reduce blood loss and the need for allogeneic blood transfusion in cardiac surgery
and orthopedic surgical procedures but few studies have assessed the efficacy of this
antifibrinolytic agent in urological endoscopic procedures.
The investigators designed this double-blind, placebo controlled study evaluate the safety
and efficacy of the antifibrinolytic agent tranexamic acid in reducing blood transfusion in
patients undergoing endoscopic surgery in urology.